君实生物单抗新适应证申报上市;默沙东2026年前三季度营收509.78亿美元|医药早参

每日经济新闻
Oct 30

丨2026年10月30日星期五丨  NO.1君实生物单抗针对尿路上皮癌的新适应证申报上市  君实生物宣布,近日国家药品监督管理局受理其自主研发的抗PD-1单抗特瑞普利单抗注射液(皮下注射)联合荣昌生物ADC药物维迪西妥单抗的新适应证上市申请,适应证为一线治疗HER2表达(HER2免疫组化IHC 1+、2+或3+)的局部晚期或转移性尿路上皮癌。  点评:本次申报为皮下剂型特瑞普利单抗与维迪西妥单抗的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10